文献速递肥胖与代谢综合征垂体与肾上腺疾病

ROHHAD(-NET)综合征全国调查:临床特征与抗ZSCAN1抗体滴度分析

Clinical characteristics and anti-ZSCAN1 antibody titer analysis in a nationwide survey of ROHHAD (-NET) syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该研究为日本全国性观察性队列研究,纳入临床诊断的ROHHAD(-NET)综合征患者,旨在明确起病或初诊时临床特征及抗ZSCAN1和抗Nax抗体滴度的意义。结果显示肥胖占72.7%,自主神经功能紊乱和中枢性低通气分别占18.2%和36.2%,初诊时血清催乳素水平在所有病例中显著升高。30例中抗体阳性率70%,抗ZSCAN1抗体滴度与神经嵴肿瘤相关,肿瘤切除或免疫抑制治疗后滴度呈下降趋势。

要点

  • ROHHAD(-NET)早期诊断需详细评估自主神经功能紊乱和低通气。
  • 初诊时血清催乳素水平显著升高,可作为提示线索。
  • 抗ZSCAN1抗体滴度与神经嵴肿瘤相关,或可反映肿瘤治疗疗效。

核心结论

  • ROHHAD(-NET)综合征早期诊断需临床详细评估自主神经功能紊乱和低通气。
  • 抗ZSCAN1抗体滴度反映神经嵴肿瘤关联,可能作为肿瘤治疗疗效的潜在标志物。
  • 建议将抗ZSCAN1抗体滴度作为ROHHAD(-NET)综合征临床管理的指标。

研究设计与样本

  • 日本全国性观察性队列研究,纳入临床诊断的ROHHAD(-NET)综合征患者。
  • 采用酶联免疫吸附法检测患者血清抗ZSCAN1和抗Nax抗体滴度。

主要发现

  • 肥胖见于72.7%的病例,自主神经功能紊乱和中枢性低通气分别见于18.2%和36.2%的病例。
  • 初诊时测量的血清催乳素水平在所有病例中显著升高。
  • 30例中抗体阳性率为70%。
  • 伴神经嵴肿瘤者的抗ZSCAN1抗体滴度显著高于无肿瘤者。
  • 一例神经嵴肿瘤患者肿瘤切除或免疫抑制治疗后抗ZSCAN1抗体滴度呈下降趋势。

临床怎么用

  • 对疑似ROHHAD(-NET)综合征患儿应详细评估自主神经功能紊乱和低通气以助早期诊断。
  • 初诊时血清催乳素显著升高可提示本病,应结合临床综合判断。
  • 检测抗ZSCAN1抗体滴度有助于提示神经嵴肿瘤关联并监测肿瘤治疗疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The early diagnosis of ROHHAD (-NET) syndrome is hard for pediatricians and endocrinologists because some symptoms, including rapid-onset obesity and autonomic dysfunction, are nonspecific and detected progressively. An autoimmune mechanism involving ZSCAN1 antibody is proposed to contribute to the pathogenesis of the disease. However, the clinical significance of the anti-ZSCAN1 antibody titer remains unestablished. OBJECTIVE: This work aims to clarify the clinical features at onset or first visit to hospitals and the significance of anti-ZSCAN1 and anti-Nax antibody titers by enzyme-linked immunosorbent assay in patient serum. METHODS: An observational cohort study was conducted of patients diagnosed clinically with ROHHAD (-NET) syndrome in Japan. RESULTS: Obesity was observed in 72.7% of cases, while autonomic dysregulation and central hypoventilation were observed in 18.2% and 36.2% of cases, respectively. Serum prolactin levels measured at the initial consultation were significantly elevated in all cases. Antibody analyses revealed positivity in 70% of 30 cases. The anti-ZSCAN1 antibody titer associated with neural crest tumors (NCTs) was significantly higher than that without tumors. In a patient with NCT, the trend of anti-ZSCAN1 antibody titer tended to be decreased after tumor resection or immunosuppressive therapy. CONCLUSION: This study suggests that we need to evaluate clinically and in detail the autonomic dysregulation and hypoventilation to diagnose ROHHAD (-NET) syndrome in its early stages. Additionally, anti-ZSCAN1 antibody titers reflect the association of NCTs and may serve as a potential marker for the efficacy of tumor therapy. We also propose the anti-ZSCAN1 antibody titer as an indicator for the clinical management of ROHHAD (-NET) syndrome.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Nakamura-Utsunomiya A, Hasegawa K, Ono T, et al. Clinical characteristics and anti-ZSCAN1 antibody titer analysis in a nationwide survey of ROHHAD (-NET) syndrome. J Clin Endocrinol Metab. 2026. PMID: 41821305. doi:10.1210/clinem/dgag109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。